New findings presented at ASH2024 suggest that a ketogenic diet and its key metabolite, β-hydroxybutyrate (BHB), may improve CAR T-cell antitumor function. In preclinical models, BHB fueled CAR T-cell metabolism, enhanced proliferation, and improved tumor control across various cancer models, including lymphoma, pancreatic cancer, and leukemia.
Importantly, a retrospective analysis of patient serum showed a positive correlation between BHB levels and CAR T-cell expansion, paving the way for a first-in-human clinical trial to assess BHB supplementation in relapsed/refractory B-cell lymphoma.
This study highlights the potential of dietary interventions to optimize immunotherapy outcomes. Thanks to all the researchers contributing to this exciting work
Thanks to the dedicated research teams and participants who made these findings possible. For more details, refer to the full presentation at ASH 2024.
For more details: https://lnkd.in/epcyPMXq
